Allergy Notes, Evidence-based Information by Board-certified Physicians

New HAE Trials and Therapies on the Horizon as of 2026

EU Greenlights Dawnzera™: RNA Therapy for Hereditary Angioedema, Following US Approval

Changing Therapeutic Landscape of HAE due to C1 inhibitor Deficiency - Twitter summary from the 2019 WSAAI meeting

International consensus on pediatric hereditary angioedema with C1-Inhibitor deficiency

Recombinant C1-esterase inhibitor Ruconest approved for hereditary angioedema (HAE)

50% of HAE patients have laryngeal swellings that are potentially fatal despite prophylaxis

Quick review of angioedema: What causes angioedema? How to treat HAE?

Hereditary angioedema (HAE) - video explanation

Icatibant subcutaneous injection (Firazyr) can be self-administered by patients upon recognition of HAE attack

Abdominal ultrasonography useful as early diagnostic tool for acute abdominal attack in hereditary angioedema (HAE)

Impaired sense of smell in hereditary angioedema

C1 esterase inhibitor dose of 20 U/kg provides rapid, effective, and safe treatment for HAE attacks

Recombinant human C1-inhibitor for treatment hereditary angioedema (HAE)

Reactions to ecallantide (Kalbitor) in some HAE patients decreased hopes that the drug could be used at home